These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 1425706)
1. A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate. Urano T; Strandberg L; Johansson LB; Ny T Eur J Biochem; 1992 Nov; 209(3):985-92. PubMed ID: 1425706 [TBL] [Abstract][Full Text] [Related]
2. Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor. Munch M; Heegaard CW; Andreasen PA Biochim Biophys Acta; 1993 Sep; 1202(1):29-37. PubMed ID: 8373822 [TBL] [Abstract][Full Text] [Related]
3. Purification of recombinant plasminogen activator inhibitor-1 in the active conformation by refolding from inclusion bodies. Lee HJ; Im H Protein Expr Purif; 2003 Sep; 31(1):99-107. PubMed ID: 12963346 [TBL] [Abstract][Full Text] [Related]
4. Plasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterisation of the recombinant intracellular and extracellular forms. Mikus P; Urano T; Liljeström P; Ny T Eur J Biochem; 1993 Dec; 218(3):1071-82. PubMed ID: 7506655 [TBL] [Abstract][Full Text] [Related]
5. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells. Lawrence D; Strandberg L; Grundström T; Ny T Eur J Biochem; 1989 Dec; 186(3):523-33. PubMed ID: 2514093 [TBL] [Abstract][Full Text] [Related]
6. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor. Lijnen HR; De Cock F; Collen D Eur J Biochem; 1994 Sep; 224(2):567-74. PubMed ID: 7925373 [TBL] [Abstract][Full Text] [Related]
7. Purification and characterization of active and latent forms of recombinant plasminogen activator inhibitor 1 produced in Escherichia coli. Seetharam R; Dwivedi AM; Duke JL; Hayman AC; Walton HL; Huckins NR; Kamerkar SM; Corman JI; Woodeshick RW; Wilk RR Biochemistry; 1992 Oct; 31(41):9877-82. PubMed ID: 1382596 [TBL] [Abstract][Full Text] [Related]
8. Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop. Audenaert AM; Knockaert I; Collen D; Declerck PJ J Biol Chem; 1994 Jul; 269(30):19559-64. PubMed ID: 8034724 [TBL] [Abstract][Full Text] [Related]
11. Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate, and cleaved forms. Sancho E; Declerck PJ; Price NC; Kelly SM; Booth NA Biochemistry; 1995 Jan; 34(3):1064-9. PubMed ID: 7827021 [TBL] [Abstract][Full Text] [Related]
12. Sodium dodecyl sulfate-induced dissociation of complexes between human tissue plasminogen activator and its specific inhibitor. Gaussem P; Grailhe P; Anglés-Cano E J Biol Chem; 1993 Jun; 268(16):12150-5. PubMed ID: 8505335 [TBL] [Abstract][Full Text] [Related]
13. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability. Lawrence DA; Olson ST; Palaniappan S; Ginsburg D Biochemistry; 1994 Mar; 33(12):3643-8. PubMed ID: 8142362 [TBL] [Abstract][Full Text] [Related]
14. Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility. Egelund R; Schousboe SL; Sottrup-Jensen L; Rodenburg KW; Andreasen PA Eur J Biochem; 1997 Sep; 248(3):775-85. PubMed ID: 9342229 [TBL] [Abstract][Full Text] [Related]
15. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator. Declerck PJ; De Mol M; Vaughan DE; Collen D J Biol Chem; 1992 Jun; 267(17):11693-6. PubMed ID: 1601844 [TBL] [Abstract][Full Text] [Related]
16. Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1. Kjøller L; Martensen PM; Sottrup-Jensen L; Justesen J; Rodenburg KW; Andreasen PA Eur J Biochem; 1996 Oct; 241(1):38-46. PubMed ID: 8898886 [TBL] [Abstract][Full Text] [Related]
17. Separation of active and inactive forms of recombinant human plasminogen activator inhibitor type 1 (PAI-1) expressed in Chinese hamster ovary cells: comparison with native human PAI-1. Strömqvist M; Andersson JO; Boström S; Deinum J; Ehnebom J; Enquist K; Johansson T; Hansson L Protein Expr Purif; 1994 Aug; 5(4):309-16. PubMed ID: 7950376 [TBL] [Abstract][Full Text] [Related]
18. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. Gils A; Knockaert I; Declerck PJ Biochemistry; 1996 Jun; 35(23):7474-81. PubMed ID: 8652525 [TBL] [Abstract][Full Text] [Related]
19. Presence of active and latent type 1 plasminogen activator inhibitor associated with porcine platelets. Lang IM; Marsh JJ; Moser KM; Schleef RR Blood; 1992 Nov; 80(9):2269-74. PubMed ID: 1421397 [TBL] [Abstract][Full Text] [Related]
20. Functional effects of single amino acid substitutions in the region of Phe113 to Asp138 in the plasminogen activator inhibitor 1 molecule. Sui GC; Wiman B Biochem J; 1998 Apr; 331 ( Pt 2)(Pt 2):409-15. PubMed ID: 9531478 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]